Riluzole
Riluzole structure
|
Common Name | Riluzole | ||
|---|---|---|---|---|
| CAS Number | 1744-22-5 | Molecular Weight | 234.198 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 296.3±50.0 °C at 760 mmHg | |
| Molecular Formula | C8H5F3N2OS | Melting Point | 116-118ºC | |
| MSDS | Chinese USA | Flash Point | 133.0±30.1 °C | |
| Symbol |
GHS06 |
Signal Word | Danger | |
|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Chem. Res. Toxicol. 23 , 171-83, (2010) Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental drug discovery projects toward safer medicines. In this st... |
|
|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
J. Sci. Ind. Res. 65(10) , 808, (2006) Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI types (hepatotoxic side effects) seen in the clinic can be tra... |
|
|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Chem. Res. Toxicol. 23 , 1215-22, (2010) Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification o... |
|
|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug Metab. Dispos. 38 , 2302-8, (2010) Drug-induced liver injury (DILI) is one of the most important reasons for drug development failure at both preapproval and postapproval stages. There has been increased interest in developing predictive in vivo, in vitro, and in silico models to identify comp... |
|
|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Nat. Chem. Biol. 3(5) , 268-273, (2007) The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain holds promise for the treatment of neurological diseases and has yielded new insight into brain cancer. However, the complete repertoire of signaling pathways ... |
|
|
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Nat. Chem. Biol. 5 , 765-71, (2009) Studies of gene function and molecular mechanisms in Plasmodium falciparum are hampered by difficulties in characterizing and measuring phenotypic differences between individual parasites. We screened seven parasite lines for differences in responses to 1,279... |
|
|
Riluzole: validation of stability-indicating HPLC, D1 and DD1 spectrophotometric assays.
J. Chromatogr. Sci. 52(6) , 539-46, (2014) A stability-indicating reversed-phase high-performance liquid chromatographic assay procedure has been developed and validated for riluzole in the presence of alkaline and oxidative degradation products. The liquid chromatographic separation was achieved and ... |
|
|
A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.
BMJ Case Rep. 2012 , doi:10.1136/bcr-2012-006868, (2012)
|
|
|
Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial.
Paediatr. Drugs 15(6) , 505-14, (2013) A hyperglutamatergic state has been shown to play a possible role in the pathophysiology of autistic disorders. Riluzole is a glutamate-modulating agent with neuroprotective properties, which has been shown to have positive effects in many neuropsychiatric di... |
|
|
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
Exp. Neurol. 255 , 96-102, (2014) Although the sodium channel blocker mexiletine is considered the first-line drug in myotonia, some patients experiment adverse effects, while others do not gain any benefit. Other antimyotonic drugs are thus needed to offer mexiletine alternatives. In the pre... |